IN VITRO AND IN VIVO PRECLINICAL MODELS FOR TESTING NEW THERAPIES FOR AZACITIDINE-RESISTANT MDS/AML.

EHA Library, Tomas Stopka, 294690

LOSS OF INTRON RETENTION INDUCES LOSS OF R-LOOPS AND REPLICATION STRESS IN SF3B1-MUTATED ERYTHROBLASTS

EHA Library, Carine Lefèvre, 294688

MODULATION OF THE IL-6/STAT3 SIGNALING AXIS IN CD4+ T CELLS REPRESENTS A IMMUNE-MEDIATED MECHANISM OF ACTION OF AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Ioannis Kotsianidis, 294687

CLINICAL IMPACTS OF GERMLINE AND SOMATIC DDX41 MUTATIONS ON MYELOID NEOPLASMS.

EHA Library, Hideki Makishima, 294686

LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR IN THIRD-LINE THERAPY OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Tamara Chitanava, 294685

BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY

EHA Library, Jorge Cortes, 294684

THE REAL–LIFE STUDY EVALUATING THE EFFICACY AND SAFETY OF PONATINIB 'TOPASE' REVEALS INDUCTION OF DEEP MOLECULAR RESPONSES IN A COHORT OF 75 TKI-RESISTANT OR INTOLERANT PATIENTS WITH CML

EHA Library, Turhan Ali, 294683

A CROSS TALK BETWEEN TREATMENT FREE REMISSION AND CML POPULATION AGING

EHA Library, Marc Delord, 294682

INDUCTION AND MAINTENANCE FOR CHRONIC MYELOID LEUKEMIA -CHRONIC PHASE: A NOVEL TREATMENT STRATEGY

EHA Library, Aditi Jain, 294681

NEXT GENERATION SEQUENCING IDENTIFIES COMMON MUTATIONAL SIGNATURES IN NOVEL GENES REPRESENTING DIFFERENT BIOLOGICAL PATHWAYS ASSOCIATED WITH ACUTE TRANSFORMATION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Zafar Iqbal, 294680

DETERMINANTS OF FIRST-LINE THERAPY CHOICE IN CHRONIC PHASE CML: A REAL-LIFE SURVEY IN ITALY

EHA Library, Mario Tiribelli, 294679

IMATINIB CORRECTS IMMUNE EXHAUSTION OF CYTOTOXIC T-LYMPHOCYTES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Fen Saj, 294678

RETROSPECTIVE INDEPENDENT REVIEW OF ARTERIAL OCCLUSIVE EVENTS (AOES) IN THE PHASE 2 PACE TRIAL OF PONATINIB IN PHILADELPHIA CHROMOSOME POSITIVE (PH+) LEUKEMIA

EHA Library, James Januzzi, 294677

Tel Aviv group

EHA Library, Elad Jacoby, 290367

Barcelona group

EHA Library, Manel Juan, 290369

Chair

EHA Library, Claudia Rössig, 290380

Real-world evidence in the EU

EHA Library, Gilles Salles, 290381

The EBMT Guidelines for practice - A framework for managing Patient Care, CRS and Neurotoxicity

EHA Library, Orla Stewart and Rose Ellard, 310514

Treatment and nursing assessment post CAR T cells in Ambulatory Care settings

EHA Library, Diana Comerford, 310513

Apheresis in adults and pediatrics

EHA Library, Daphna Hutt, 290366

Cytopenia

EHA Library, Marion Subklewe, 290384

Patient selection and harvesting the CAR

EHA Library, Marlène Vercasson, 310512

A CAR-T for Everything - overview of current studies and indications

EHA Library, Rebecca Davies, 310511

What is driving CARs into the spotlight - the science simplified

EHA Library, Elaine Vickers, 310510

imSAVAR

EHA Library, Ulrike Köhl, 290406

Post Authorization Safety Studies for approved CAR-T products

EHA Library, Anja van Biezen, 290386

CAR T data collection - CIBMTR experience

EHA Library, Marcelo Pasquini, 290377

Creating a country-wide selection algorithm - The Austrian experience

EHA Library, Ulrich Jäger, 290404

Marketing authorization for CAR T cells - The EMA perspective

EHA Library, Martina Schüssler-Lenz, 290382

Visualizing CAR T cells at work

EHA Library, Johannes Huppa, 290365

Chair

EHA Library, Ibrahim Yakoub-Agha, 290407

Current CAR T trial activities in China

EHA Library, Jianxiang Wang, 290388

O2.8 LONG-TERM FOLLOW-UP OF A PHASE 1, FIRST-IN-HUMAN OPEN-LABEL STUDY OF LCAR-B38M, A STRUCTURALLY DIFFERENTIATED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING B-CELL MATURATION ANTIGEN (BCMA), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, J Liu, 290400

O2.3 ARE CAR TS THE SAME? EVIDENCE FROM EUROPEAN HTA REVIEWS

EHA Library, K Lykopoulos, 290398

O2.2 A PLATFORM FOR CAR-TREG GENERATION FOR AUTOIMMUNE DISEASES

EHA Library, M Doglio, 290397

iPS CARs

EHA Library, Maria Themeli, 290385

L1CAM-specific CAR T cell therapy for childhood neuroblastoma

EHA Library, Annette Künkele, 290372

Updates in CAR T cell therapy

EHA Library, Carl June, 290370

ROR1 CAR T cell therapy in CLL and solid tumors

EHA Library, Jennifer Specht, 290383

O1.4 INTEGRATED DRUG PROFILING AND CRISPR SCREENING IDENTIFY ESSENTIAL PATHWAYS FOR CAR T CELL CYTOTOXICITY

EHA Library, Mikko Keränen, 290391

O1.5 A NEW PROMISING THIRD GENERATION CAR-CD30 T-CELL THERAPY FOR CD30+ LYMPHOMAS

EHA Library, B De Angelis, 290392

O1.7 HAMPERING TUMOR GLYCOSYLATION IMPROVES THE EFFICACY OF CAR-T CELLS AGAINST SOLID TUMORS

EHA Library, Camilla Sirini, 290394

O1.9 EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA

EHA Library, Marie Jose Kersten, 290396

Improved CAR T cell approaches for lymphoid malignancies

EHA Library, Martin Pule, 290378

Introduction & welcome

EHA Library, Faculty / Presenters, 290403

HemaSphere

EHA Library, EHA Delegate, 276201

New treatment strategies in multiple myeloma

EHA Library, Philippe Moreau, 273551

NGS technologies in AML: Time to use in clinical care?

EHA Library, Torsten Haferlach, 273550

Gene therapy for hematological disorders

EHA Library, Olivier Hermine, 273549

ASCEND PHASE 3 STUDY OF ACALABRUTINIB VS INVESTIGATOR’S CHOICE OF RITUXIMAB PLUS IDELALISIB (IDR) OR BENDAMUSTINE (BR) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Paolo Ghia, 273259

IN STROKE-FREE CHILDREN WITH SICKLE CELL ANEMIA AND CEREBRAL VASCULOPATHY, THE OUTCOME OF STENOSIS WAS SIGNIFICANTLY BETTER AFTER TRANSPLANTATION THAN ON CHRONIC TRANSFUSION IN A PROSPECTIVE TRIAL

EHA Library, Francoise Bernaudin, 273258

EARLY HEMATOPOIESIS TRANSLATES MICROBIAL SIGNALS TO INTESTINAL TISSUE REPAIR

EHA Library, Hitoshi Takizawa, 273257

ONTOGENIC CHANGES IN HEMATOPOIETIC HIERARCHY DETERMINES PEDIATRIC SPECIFICITY AND DISEASE PHENOTYPE IN FUSION ONCOGENE-DRIVEN MYELOID LEUKEMIA

EHA Library, Cécile Lopez, 273256

DEVELOPMENT OF A CLINICAL PREDICTION RULE FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACUTE LEUKEMIA

EHA Library, Alejandro Lazo-Langner, 274194

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EALRY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL

EHA Library, Petra Langerbeins, 273255

A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Shaji Kumar, 273254

HM-PRO

EHA Library, Edward Laane, 274168

CAR-T cells in MM

EHA Library, Hermann Einsele, 274163

New contact system-inhibiting anticoagulant drugs that might not increase bleeding

EHA Library, Nicola Mutch, 274244

Treatment of high risk follicular lymphoma

EHA Library, Wojciech Jurczak, 273684

Novel prognostic tools that identify high risk follicular lymphoma

EHA Library, Stefano Luminari, 273683

Follicular lymphoma genomics

EHA Library, Jessica Okosun, 273682

Stem cell derived NK cell therapy

EHA Library, Harry Dolstra, 273669

Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute graft-versus-host disease

EHA Library, Anastasios Karadimitris, 273668

Mechanisms of action for different checkpoint inhibitors

EHA Library, Pedro Berraondo, 273667

Clinical value of new drugs in acute myeloid leukemia

EHA Library, Gert Ossenkoppele, 273660

Early response evaluation in AML using mass cytometry

EHA Library, Bjorn Tore Gjertsen, 273659

Epigenetics, DNA damage and immune modulation in the molecular landscape of AML

EHA Library, Feyruz Rassool, 273658

THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY

EHA Library, Francesca Schieppati, 267400

INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING ANTI-CD 19 CHIMERIC ANTIGEN RECEPTORS T-CELLS (CAR T) FOR DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). A MONOCENTRIC PRELIMINARY EXPERIENCE.

EHA Library, Roberta Di Blasi, 267395

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY

EHA Library, Pier Luigi Zinzani, 267355

FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES

EHA Library, Valentín Ortiz-Maldonado, 267390

UNEXPECTED DIFFERENCES IN CARDIAC IRON METABOLISM AND SURVIVAL IN HAMP-KO AND FPN(C326S) MICE

EHA Library, Sandro Altamura, 267385

SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

EHA Library, Cristina J. Gasparetto, 267360

INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK

EHA Library, Andrew Innes, 267380

MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Mohamad Jawhar, 267365

CLINICAL EFFICACY OF A NOVEL VALIDATED PROGNOSTIC INDEX FOR TRIAL DESIGN IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA.

EHA Library, Anthony Moorman, 267375

MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

EHA Library, Frank G. Rücker, 267370

NEUTROPHIL TO LYMPHOCYTE RATIO, PLATELET TO LYMPHOCYTE RATIO, AND RISK OF THROMBOEMBOLISM IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY

EHA Library, Vladimir Otasevic, 267399

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

EHA Library, Catherine Thieblemont, 267354

POLYMORPHISMS IN CYTOKINES, CHEMOKINES AND THEIR RECEPTORS GENES CONTRIBUTED TO CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Miren Vallejo, 267394

ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA

EHA Library, Francesca del bufalo, 267389

HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)

EHA Library, Paul G. Richardson, 267359

A PHASE IIA STUDY TO EVALUATE THE SAFETY, PK AND PD OF REPEATED ADMINISTRATIONS OF THE HEPCIDIN ANTAGONIST PRS-080 IN ANEMIC CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HEMODIALYSIS

EHA Library, Lutz Renders, 267384

REDUCTION OF GRAFT-VERSUS-HOST DISEASE USING DUAL LYMPHOCYTE SUPPRESSION WITH ANTI-THYMOCYTE GLOBULIN AND LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL PATIENTS AT HIGH GVHD RISK

EHA Library, Yu Wang, 267379

MASKED POLYCYTHEMIA VERA: ANALYSIS OF A SINGLE CENTER SERIES OF 2480 RED CELL MASSES.

EHA Library, Juliette SORET-DULPHY, 267364

NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.

EHA Library, Anna CANDONI, 267374

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

EHA Library, Naval Daver, 267369

BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH B­CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP­ALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS

EHA Library, Nicola Goekbuget, 267373

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

EHA Library, Linus Angenendt, 267368

A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS

EHA Library, Andrea Bacigalupo, 267378

THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Trine Alma Knudsen, 267363

ERFE-A260S ACCOUNTS FOR HEPATIC IRON METABOLISM IMPAIRMENT BY ACTING ON THE BMP-SMAD PATHWAY

EHA Library, Roberta Russo, 267383

A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

EHA Library, M. Lia Palomba, 267388

EFFECTIVENESS OF DENOSUMAB COMPARED TO ZOLEDRONIC ACID IN BONE DISEASE TREATMENT OF MULTIPLE MYELOMA (MM): A META-ANALYSIS

EHA Library, James Abraham Malala, 267358

SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY

EHA Library, Koji Kawamura, 267393

ASSOCIATION OF SYSTEMIC CYTOKINE LEVELS WITH RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH GLIOMA

EHA Library, Pegah Mir Seyed Nazari, 267398

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY

EHA Library, Pieternella (Elly) Lugtenburg, 267353

INTESTINAL MICROBIOTA CAN PREDICT AGVHD FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Lijie Han, 267377

RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110)

EHA Library, Frank Stegelmann, 267362